<DOC>
	<DOCNO>NCT01878526</DOCNO>
	<brief_summary>The investigator purpose define prevalence omeprazole resistance gastroesophageal reflux disease ( GERD ) systemic sclerosis ( SSc ) , compare efficacy omeprazole combination algycon versus omeprazole combination domperidone severity reflux symptom omeprazole resistant GERD SSc , compare efficacy omeprazole combination algycon versus omeprazole combination domperidone frequency symptoms omeprazole- resistant GERD SSc .</brief_summary>
	<brief_title>Gastroesophageal Reflux Treatment Scleroderma</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Domperidone</mesh_term>
	<mesh_term>Alginic acid</mesh_term>
	<criteria>Phase 1 SSc patient fit inclusion exclusion criterion eligible phase 1 study evaluation prevalence omeprazole resistantGERD Inclusion criterion : 1 . SSc patient age 18 65 year . 2 . Clinically diagnosed GERD GERDquestionnaire score &gt; 3 3 . Must receive proton pump inhibitor ( PPI ) prokinetic drug within 2 week baseline evaluation Exclusion criterion : 1 . Pregnancy lactation 2 . Previous history gastroesophageal surgery endoscopic therapy due severe erosive esophagitis 3 . Present Barrett 's esophagus 4 . Bedridden confine selfcare 5 . Evidence active malignant disease 6 . Present uncontrolled severe medical problem asthma , angina , hepatic renal disease 7 . Present active infection need systemic antibiotic 8 . Allergic history omeprazole 9 . Receiving prohibit comedications may drug interaction attenuate GERD symptom tetracycline , ferrous salt , digoxin , isoniacid , oral bisphosphonate Phase 2 randomize parallel study SSc patient fit inclusion exclusion criterion eligible phase 2 study . Inclusion criterion : 1 . SSc patient complete phase 1 study . 2 . The subject define PPIresistance . 3 . The subject must willing continue phase 2 study . Exclusion criterion : 1 . Pregnancy 2 . Present uncontrolled severe medical problem 3 . Present active infection 4 . Allergic history alginic acid domperidone 5 . Receiving prohibit comedications may drug interaction attenuate GERD symptom tetracycline , ferrous salt , digoxin , isoniacid , oral bisphosphonate 6 . Chewing difficulty</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>gastroesophageal reflux disease</keyword>
	<keyword>heart burn</keyword>
	<keyword>regurgitation</keyword>
	<keyword>systemic sclerosis</keyword>
	<keyword>scleroderma</keyword>
	<keyword>proton pump inhibitor</keyword>
	<keyword>alginic acid</keyword>
	<keyword>omeprazole</keyword>
	<keyword>prokinetic</keyword>
</DOC>